FAQ on Kairos Pharma Ltd.'s Presentation of KROS 101 Data at 2025 ASCO Annual Meeting

What is KROS 101?

KROS 101 is a small molecule GITR ligand agonist being studied for its effect on T effector cells, T reg cells, and intratumoral CD8 T cell cytotoxicity, with potential applications in cancer treatment.

When and where will Kairos Pharma present the KROS 101 data?

The data will be presented on June 2, 2025, at McCormick Place in Chicago during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Why is the presentation of KROS 101 data significant?

The presentation is significant as it provides an opportunity to share findings and advance discussions on KROS 101’s potential in optimizing cancer treatment, offering hope for new therapeutic approaches.

Who is the CEO of Kairos Pharma Ltd.?

John Yu, M.D., is the CEO of Kairos Pharma Ltd., who highlighted the importance of sharing KROS 101 findings at the ASCO Annual Meeting.

What is Kairos Pharma Ltd.’s lead candidate and its purpose?

Kairos Pharma’s lead candidate is ENV105, an antibody targeting CD105, aimed at reversing drug resistance and restoring the effectiveness of standard therapies across multiple cancer types.

Where can I find more information about Kairos Pharma Ltd.?

More information about Kairos Pharma Ltd. can be found on their website at www.KairosPharma.com or in the company’s newsroom at https://ibn.fm/KAPA.

What are the current clinical trials involving ENV105?

ENV105 is currently in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs.

How does InvestorWire contribute to Kairos Pharma’s communication?

InvestorWire provides advanced wire-grade press release syndication and a suite of corporate communications solutions to help Kairos Pharma reach a wide audience of investors and the general public.